Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alcon

- PMLiVE

Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

An inflection point for MET-inhibitor class

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

Novartis day

FDA clears Novartis’ new breast cancer drug Piqray

Blockbuster potential for PI3K drug

- PMLiVE

Novartis sees five new $1bn-plus launches in next two years

CEO defends likely high price of Zolgensma

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Novartis builds case for SMA gene therapy as FDA verdict looms

One shot therapy provided rapid improvement in motor function

- PMLiVE

Alcon spun off, leaner Novartis raises profit forecast

Expects three new launches in 2019

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Bad news for BMS as Keytruda kidney cancer combo approved

Opdivo and Yervoy combination will be squeezed

- PMLiVE

Novartis makes case for gene therapy Zolgensma in SMA

New data revealed ahead of FDA review

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links